ClinicalTrials.gg
Active, not recruitingNCT07684898Updated Sep 4, 2026

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

A Phase 3 interventional study of FRSW107 in Severe Hemophilia A, sponsored by Hangzhou Gensciences Biopharmaceutical Co., Ltd.. Active, not recruiting at 19 sites in China. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Planned enrollment
33rd of 80
60 · median 54
Started
2026
with 8 others
Phase 3
41 of 93
9 open now
Primary completion
2027-03
later than 18 of 38 live
Registered
92nd of 93
by date

Among the 93 studies in Hemophilia A with a site in China, this one is the 33rd largest by planned enrollment of the 80 interventional ones that give a count, is one of 9 that started in 2026, is one of 41 in phase 3, reaches primary completion later than 18 of the 38 other live ones, and was the 92nd registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

The indication for this product is to control and prophylaxis in patients with Hemophilia A (congenital Factor VIII deficiency):

The Primary Objective: To evaluate the efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) for prophylactic treatment in previously treated patients with severe Hemophilia A.

Secondary Objectives: To evaluate the health-related quality of life, pharmacokinetic (PK) profiles, safety and immunogenicity of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) for prophylactic treatment in previously treated subjects with severe Hemophilia A.

03

Conditions studied

  • Severe Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.12≤ age ≤65 year-old men; 2.Subjects with clinically confirmed severe hemophilia A, i.e. at screening (central laboratory testing) or previous medical records confirm: FⅧ activity \< 1%; 3.Previous documented treatment with any recombinant and/or blood-derived coagulation factor Ⅷ products or cryoprecipitation products and dosed ≥150 exposure days (EDs≥150) ; 4.Normal (PT) or International Normalized Ratio (INR)\<1.3; 5.Bleeding events were recorded in detail for at least 6 months prior to screening; 6.Fully understand and know about this study and sign to participate in the clinical study voluntarily, subject and/or their guardian can cooperate with them for bleeding treatment at home, and have the ability to complete all study procedures

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to the drug or its , including mouse or hamster proteins;
  2. or anaphylaxis after FⅧ or IgG2 injection in the past;
  3. FⅧ inhibitor positive (≥0.6 BU/mL) during the screening period, or have a history of FⅧ inhibitor positive in the past, or a family history of FⅧ inhibitor positive;
  4. Von Willebrand factor (vWF) antigen test results were lower than the lower limit of normal value;
  5. Severe anemia at the screening stage ( \< 60 g/L);
  6. count during screening period \< 100×109 /L;
  7. Abnormal liver function: (ALT), or aspartate aminotransferase (AST) >3 times (ULN); or Serum total (TBIL) >1.5x ULN;
  8. Subjects with abnormal renal function: (Ccr) \<50 ml/min (according to Cockcroft and Gault formula); or Serum creatinine (Cr) >1.5x ULN;
  9. Subjects with active , that is, hepatitis C virus (HCV) antibody positive and HCV RNA positive; Or anti-treponema pallidum specific antibody (TPHA) positive; Or positive for antibodies against the (HIV);
  10. Subjects with coagulation dysfunction other than hemophilia A;
  11. Have a medical condition that may increase the risk of bleeding;
  12. A history of drug or alcohol abuse;
  13. Have a known mental disorder that may affect trial compliance;
  14. Subjects who have received transfusions of blood or blood components within 4 weeks prior to screening;
  15. Participants who had participated in other Interventional clinical trials within 1 month before screening;
  16. Use of any anticoagulant or antiplatelet drugs, off-label maximum dose of non-steroidal anti-inflammatory drugs (NSAID) within 7 days prior to screening; Or subjects who need to be treated with anticoagulant or antiplatelet drugs or off-label maximum doses of SAID during clinical trials;
  17. Severe cardiovascular and cerebrovascular disease or major thromboembolic events, such as stroke, myocardial infarction, unstable angina, congestive heart failure ( [NYHA] grade ≥ III), and severe arrhythmias (including interphase > 480 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic ≥ 160 mmHg or diastolic ≥100 mmHg), deep vein thrombosis, etc.
  18. Subjects who have received emicizumab within 6 months prior to the first administration of study drug, or have previously received fitusiran (siRNA, brand name: CEPHEIN®) or gene therapy;
  19. Subjects who have received monoclonal antibody therapy, Fc fusion protein products, or intravenous immunoglobulin within 3 months prior to the first administration of study drug;
  20. Subjects who have undergone major surgery within 3 months prior to the first administration of study drug, or those who plan to receive surgery during the study period;
  21. Subjects who have received any standard half-life FⅧ preparations (e.g., Advate, Kovaltry, Octate, Recombinate, NovoEight, Anjiyin, etc.) within 3 days or 5 half-lives (whichever is longer) prior to the first administration of study drug; patients who have received any other extended half-life FⅧ preparations (e.g., Noxyte) within 4 days or 5 half-lives (whichever is longer) prior to the first administration of study drug;
  22. Study patients with fever, severe active bacterial or viral infection, and allergies within 2 weeks before the first administration of the drug;
  23. Systemic immunomodulators (such as [> 10 mg/ day equivalent dose of prednisone], alpha-interferon, immunoglobulin, cyclophosphamide, cyclosporin, etc.) used within 14 days prior to the first administration of the study drug or planned during the study period were allowed to be inhaled, nasal spray, or topical corticosteroids;
  24. Those who had been vaccinated within 4 weeks prior to initial administration of the study drug; Or who plan to be vaccinated during PK blood collection (only for subjects in the PK subgroup);
  25. Plan to have a child or sperm donation during the entire trial period and within 3 months after the last dose, or do not want to use effective physical (such as condoms, diaphragms, Iuds, etc.);
  26. Have other serious medical conditions that the researchers said could not benefit from them
  27. Subjects deemed unsuitable by other investigators.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    prophylactic treatment

    Subjects in PK Subgroup receive a single and multiple dose of 50 IU/kg FRSW107 at Visit 1 and Visit 5, respectively. PK samples will be collected up to 72 hours after the start of administration.After completion of PK blood sampling for the first dose and prior to availability of the corresponding PK data, subjects may continue prophylactic treatment with FRSW107 at a dose of 50 IU/kg every 3 days until their PK data are obtained.Once the first-dose PK data of a subject are available, individualized prophylactic treatment with FRSW107 will be implemented based on the PK results. On the premise of maintaining a trough FVIII activity level of ≥1%, the investigator will determine the appropriate individualized prophylactic regimen for the subject. The recommended prophylactic dosing interval is Q3D, with an optional dose range of 25-50 IU/kg. For subjects in the non-PK subgroup, the investigator will select the initial prophylactic dose within the recommended range of 25-50 IU/kg.

    Drug: FRSW107

Interventions

  • For subjects in the PK subgroup: they will receive a dose of 50 IU/kg at the first dose visit 1 to obtain preliminary pharmacokinetic (PK) data. After assessment by the investigator, individualized prophylactic treatment (25\~50 IU/kg, Q3D) will be administered to maintain the trough concentration of FVIII activity at ≥1%. For subjects not in the PK subgroup: they will receive prophylactic treatment at a dose of 25\~50 IU/kg once every three days. If a subject experiences a breakthrough bleeding episode requiring treatment, the investigator shall determine the appropriate dosage (recommended dose range: 20\~50 IU/kg) and administration frequency.

06

What researchers measure

Primary outcomes

  1. ABR

    Annual rate of bleeding (ABR) during preventive treatment = Number of bleeding episode during the efficacy evaluation period/(number of treatment days /365.25)

    Time frame: 6 months

Secondary outcomes

  1. Safety Evaluation

    Incidence of positive FⅧ inhibitor (key secondary endpoint)

    Time frame: 6 months

  2. Immunogenicity Evaluation

    Incidence of positive anti-FRSW107 antibodies and anti-CHO antibodies; for subjects with positive anti-FRSW107 antibodies, additional testing for anti-rhFVIII antibodies shall be performed to assess their positive incidence.

    Time frame: 6 months

  3. Peak activity (Cmax)

    Applicable to PK Subgroup: 1. Single administration: Peak activity (Cmax). 2. Multiple administrations: Cmax.

    Time frame: At Visit 1 (Day 0 through Day 4) and Visit 5 (Day 160 through Day 164).

  4. Effective rate of hemostatic treatment

    During the prophylactic treatment period, breakthrough hemostatic therapy was evaluated based on a four-level scoring scale (excellent, good, moderate, ineffective), with scores of "excellent" or "good" indicating efficacy.

    Time frame: 6 months

  5. Annualized rate of spontaneous bleeds and annualized rate of traumatic bleeds.

    Annualized rate of spontaneous bleeds and annualized rate of traumatic bleeds.

    Time frame: 6 months

  6. Annualized Joint Bleed Rate (AJBR)

    Annualized Joint Bleed Rate (AJBR), including overall AJBR, annualized rate of spontaneous joint bleeds and annualized rate of traumatic joint bleeds. AJBR = Number of joint bleeds during efficacy evaluation period / (Number of treatment days / 365.25).

    Time frame: 6 months

  7. Number of target joints.

    Number of target joints. Target joint definition: A joint with ≥3 spontaneous bleeds within any consecutive 6 months is defined as a target joint; a joint will no longer be classified as a target joint if it experiences ≤2 bleeds within any consecutive 12 months.

    Time frame: 6 months

  8. Dosing parameters of prophylactic treatment

    Dosing parameters of prophylactic treatment: total cumulative dose during study, annual total dose, mean dose per prophylactic administration; administration frequency: total number of injections, mean annual injection frequency; dosing interval: mean interval between prophylactic administrations throughout the prophylaxis period.

    Time frame: 6 months

  9. Factor VIII incremental recovery and trough levels during prophylactic treatment.

    Factor VIII incremental recovery and trough levels during prophylactic treatment.

    Time frame: 6 months

  10. Time interval between each bleeding episode and the prior prophylactic dose during prophylaxis.

    Time interval between each bleeding episode and the prior prophylactic dose during prophylaxis.

    Time frame: 6 months

  11. Dosing parameters for rescue hemostatic treatment of breakthrough bleeds during prophylaxis

    Dosing parameters for rescue hemostatic treatment of breakthrough bleeds during prophylaxis: mean dose, total cumulative dose and total number of administrations.

    Time frame: 6 months

  12. Hemophilia Joint Health Score version 2.1 (HJHS 2.1)

    Hemophilia Joint Health Score version 2.1 (HJHS 2.1): total HJHS 2.1 score, individual domain subscores, and their respective changes from baseline.

    Time frame: 6 months

  13. EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) and EuroQol Visual Analogue Scale (EQ VAS) .

    EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) and EuroQol Visual Analogue Scale (EQ VAS), together with their changes from baseline.The total healthy utility index score ranges of EQ-5D-5L from a minimum value of 0 points to a maximum value of 1 points,higher scores mean a better outcome.The total score ranges of EuroQol Visual Analogue Scale (EQ VAS) from a minimum value of 0 points to a maximum value of 100 points,higher scores mean a better outcome.

    Time frame: 6 months

  14. Incidence of insufficient therapeutic response

    Incidence of insufficient therapeutic response.

    Time frame: 6 months

  15. time to peak (Tmax)

    Applicable to PK Subgroup: 1. Single administration: time to peak (Tmax). 2. Multiple administrations: Tmax.

    Time frame: At Visit 1 (Day 0 through Day 4) and Visit 5 (Day 160 through Day 164).

  16. area under the concentration-time curve from time zero to the last quantifiable time point (AUC₀-ₗₐₛₜ)

    Applicable to PK Subgroup: 1. Single administration: area under the concentration-time curve from time zero to the last quantifiable time point (AUC₀-ₗₐₛₜ). 2. Multiple administrations: AUC₀-ₗₐₛₜ.

    Time frame: At Visit 1 (Day 0 through Day 4) and Visit 5 (Day 160 through Day 164).

  17. elimination half-life (t₁/₂)

    elimination half-life (t₁/₂)

    Time frame: At Visit 1 (Day 0 through Day 4) and Visit 5 (Day 160 through Day 164).

  18. incremental recovery

    incremental recovery (calculated based on FⅧ Cmax measured after the end of infusion, unit: \[IU/dL\]/\[IU/kg\])

    Time frame: At Visit 1 (Day 0 through Day 4) and Visit 5 (Day 160 through Day 164).

  19. The time for FⅧ activity to decline to 15%, 5%, 3% and 1% .

    The time for FⅧ activity to decline to 15%, 5%, 3% and 1% respectively after study drug infusion.

    Time frame: At Visit 1 (Day 0 through Day 4) and Visit 5 (Day 160 through Day 164).

07

Study locations

19 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2027, 8 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 8 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jul 6, 2026
StartActual
Jun 12, 2026
Primary completionEst.
Mar 9, 2027
CompletionEst.
Jun 21, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07684898
Lead sponsor
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jun 12, 2026
Primary completion
Mar 9, 2027 (estimated)
Completion
Jun 21, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Renchi Yang, PhD
study chair · Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FRSW107

Start the discussion